ALKS:NASDAQ
Alkermes Plc
48,33 $
arrow_upward
+0,65%(+0,31) 1D
48,33 $
0,00% (0,00)
bedtimeAfter hours
Closed: 21 օգս, 16:00:01 GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALKS...
Open
48,05 $
High
48,67 $
Low
47,33 $
Mkt. cap
8,11 մլրդ
Avg. vol.
1,63 մլն
Volume
939,64 հզր
P/E ratio
125,57
52-wk high
55,67 $
52-wk low
25,16 $
EPS
0,38 $
Beta
0,31
Shares outstanding
167,76 մլն
No. of employees
2 հզր
Open
48,05 $
High
48,67 $
Low
47,33 $
Mkt. cap
8,11 մլրդ
Avg. vol.
1,63 մլն
Volume
939,64 հզր
P/E ratio
125,57
52-wk high
55,67 $
52-wk low
25,16 $
EPS
0,38 $
Beta
0,31
Shares outstanding
167,76 մլն
No. of employees
2 հզր
News stories
From web sources and news partners
GuruFocus
·
1 օր առաջ
Alkermes PLC (ALKS) Shares Fall 4.4% -- What GF Score of 64 Tells Investors
Profile
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
About Alkermes Plc
CEORichard F. Pops | Richard F. Pops
Employees2,05 հզր
Founded1987
Headquarters-
Sector-
Websitealkermes.com
AI content may include mistakes. Learn more